Repair of endothelial glycocalyx

Patent metadata

Field	Value
Publication number	US-2025120998-A1
Application number	US-202418917505-A
Country	US
Kind code	A1
Filing date	Oct 16, 2024
Priority date	Oct 17, 2023
Publication date	Apr 17, 2025
Grant date	—

Abstract

Compositions and methods relating to glycosaminoglycan components are disclosed. For example, a composition including glycosaminoglycan components are administered to organs before, during, or after ex vivo organ perfusion to improve organ transplantation. The improvements include reduced MMP levels, reduced apoptotic markers, reduced endothelial activation, and increased organ function. Such methods and compositions are useful for organ and tissue transplantation and storage or shipment of harvested organs and tissues.

First claim

What is claimed is:

1 . A composition for treating an organ, comprising an effective amount of at least one glycosaminoglycan component.

2 . The composition of claim 1 , wherein the at least one glycosaminoglycan component comprises high molecular weight hyaluronic acid, sulodexide, or a combination of high molecular weight hyaluronic acid and sulodexide.

3 . The composition of claim 2 , further comprising at least one additional component selected from the group consisting of: isolated mitochondria, total parenteral nutrition (TPN), an antioxidant and a thrombolytic agent.

4 . The composition of claim 3 , wherein the antioxidant is N-acetyl cysteine.

5 . The composition of claim 3 , wherein the thrombolytic agent is human tissue type plasminogen activator.

6 . A method of treating an organ, comprising contacting the organ with a composition of claim 1 .

7 . The method of claim 6 , wherein the glycosaminoglycan components comprise high molecular weight hyaluronic acid, sulodexide, or a combination of high molecular weight hyaluronic acid and sulodexide.

8 . The method of claim 7 , wherein high molecular weight hyaluronic acid is present in an amount of 0.01 mg to 15 mg.

9 . The method of claim 7 , wherein sulodexide is present in an amount of 0.067 mg/kg to 30 mg/kg.

10 . The method of claim 7 , wherein the composition further comprises isolated mitochondria, total parenteral nutrition (TPN), an antioxidant and/or a thrombolytic agent.

11 . The method of claim 6 , wherein contacting the organ comprises perfusing the organ with the composition.

12 . The method of claim 11 , wherein the organ is perfused with the composition for at least one hour.

13 . The method of claim 6 , wherein contacting the organ comprises administration of one or more doses of the composition to the organ before transplantation.

14 . The method of claim 13 , wherein contacting the organ occurs at a time selected from the group consisting of: (a) after procurement of the organ from a donor, (b) before shipment of the organ, (c) before EVLP, (d) during EVLP, (e) after EVLP, and (f) immediately before transplant.

15 . The method of claim 6 , wherein the organ exhibits a decrease in circulating MMP, markers of apoptosis, and/or endothelial cell activation compared to an organ perfused with a solution lacking glycosaminoglycan components.

16 . The method of claim 6 , wherein the organ is a lung, a liver, or a kidney.

17 . The method of claim 6 , wherein the organ is a bioengineered organ.

18 . The method of claim 6 , wherein an initial dose of high molecular weight hyaluronic acid is administered at hour 1 of ex vivo organ perfusion and optionally additional doses administered every 6 hours following the initial dose.

19 . The method of claim 7 , wherein an initial dose of sulodexide is administered at either hour 1 or hour 2 of ex vivo organ perfusion, and optionally additional doses administered hourly following the initial dose.

20 . The method of claim 6 , wherein the contacting the organ comprises delivering the composition to the airway of the organ.

Assignees

• United Therapeutics Corp

Inventors

• Hogan Sarah
• Guthrie Kelly
• Bonvillain Ryan
• Givens Chris
• Petersen Thomas

Classifications

• C12Y304/21068

  Tissue plasminogen activator (3.4.21.68), i.e. tPA · CPC title

• A61K38/49

  Urokinase; Tissue plasminogen activator · CPC title

• A61K31/737

  Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K31/727 takes precedence) · CPC title

• A61K31/198

  Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00) · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title